ALNYLAM PHARMACEUTICALS, INC. Logo

ALNYLAM PHARMACEUTICALS, INC.

Pioneering RNAi gene-silencing therapies for rare genetic and cardiometabolic diseases.

ALNY | US

Overview

Corporate Details

ISIN(s):
US72703U1025 (+1 more)
LEI:
Country:
United States of America
Address:
675 WEST KENDALL STREET, 2142 CAMBRIDGE
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company pioneering the development and commercialization of RNA interference (RNAi) therapeutics. This novel class of medicines utilizes a natural biological process to silence specific genes, thereby preventing the production of proteins that cause or contribute to human disease. The company's portfolio of approved medicines targets a range of rare genetic, cardiometabolic, and hepatic infectious diseases, with key products including ONPATTRO®, AMVUTTRA®, GIVLAARI®, and OXLUMO®. Alnylam continues to advance a robust clinical pipeline to address diseases with high unmet medical need, solidifying its leadership in translating RNAi science into transformative treatments for patients globally.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all ALNYLAM PHARMACEUTICALS, INC. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for ALNYLAM PHARMACEUTICALS, INC.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for ALNYLAM PHARMACEUTICALS, INC. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Company Country Ticker View
Jasper Therapeutics, Inc. Logo
Develops mast cell-depleting antibody therapies for chronic diseases and stem cell transplants.
United States of America JSPR
Jazz Pharmaceuticals plc Logo
Develops medicines for serious diseases in neuroscience and oncology.
United States of America JAZZ
Develops therapies for rare genetic diseases, CNS disorders, and regenerative medicine.
Japan 4552
JEIL PHARMACEUTICAL CO.,LTD Logo
Global manufacturer of pharmaceutical APIs, antibiotics, and injection-based treatments.
South Korea 271980
JEIL PHARMA HOLDINGS INC. Logo
Develops and distributes APIs, generics, and modified drugs, specializing in injections.
South Korea 002620
JETEMA Co.,Ltd. Logo
Research-driven developer of aesthetic toxins, dermal fillers, and threads.
South Korea 216080
Develops and manufactures high-tech drugs for cancer, diabetes, and a range of diseases.
South Korea 007370
JOHNSON & JOHNSON Logo
Develops innovative medicines and medical technologies for complex diseases and personalized care.
United States of America JNJ
Journey Medical Corp Logo
A pharmaceutical firm commercializing prescription drugs and generics for dermatology.
United States of America DERM
JUPITER NEUROSCIENCES, INC. Logo
Pharma firm developing resveratrol treatments for neuroinflammation and rare diseases.
United States of America JUNS

Talk to a Data Expert

Have a question? We'll get back to you promptly.